澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Cellmid

0.056

0.000

成交量：- -

成交额：3,678.25

市值：1,237.60万

市盈率：-3.29

高：0.056

开：0.056

低：0.056

收：0.056

52周最高：0.056

52周最低：0.056

股本：2.21亿

流通股本：1.46亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.017

每股收益(LYR):-0.024

净资产收益率：-37.59%

总资产收益率：-14.43%

市净率：1.19

市盈率(LYR):-2.33

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Cellmid

交易所：

ASX

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.cellmid.com.au

邮编：

- -

电话：

- -

传真：

- -

简介：

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CDY.AU/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CDY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CDY.AU\",,,,,undefined,":{"symbol":"CDY.AU","market":"AU","secType":"STK","nameCN":"Cellmid","latestPrice":0.056,"timestamp":1771995600000,"preClose":0.056,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Cellmid","floatShares":146143717,"shares":221000000,"eps":-0.017,"marketStatus":"未开盘","change":0,"latestTime":"02-25 16:00:00 AEDT","open":0.056,"high":0.056,"low":0.056,"amount":3678.248032956,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.017,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CDY.AU\",,,,,undefined,":{"symbol":"CDY.AU","floatShares":146143717,"roa":"-14.43%","roe":"-37.59%","lyrEps":-0.023984,"shares":221000000,"dividePrice":0,"high":0.056,"amplitude":0,"preClose":0.056,"low":0.056,"week52Low":0.056,"pbRate":"1.19","week52High":0.056,"institutionHeld":0,"latestPrice":0.056,"eps":-0.017,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.017,"open":0.056,"prevYearClose":0.056,"prevWeekClose":0.056,"prevMonthClose":0.056,"prevQuarterClose":0.056,"fiveDayClose":0.056,"twentyDayClose":0.056,"sixtyDayClose":0.056},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDY.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDY.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.cellmid.com.au","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0449},{"period":"6month","weight":0.0805},{"period":"1year","weight":0.222},{"period":"ytd","weight":0.0255}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4375,"avgChangeRate":0.056986},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.006186},{"month":3,"riseRate":0.466667,"avgChangeRate":0.042147},{"month":4,"riseRate":0.1875,"avgChangeRate":-0.055528},{"month":5,"riseRate":0.25,"avgChangeRate":-0.065543},{"month":6,"riseRate":0.6875,"avgChangeRate":0.098275},{"month":7,"riseRate":0.1875,"avgChangeRate":-0.064999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.000407},{"month":9,"riseRate":0.3125,"avgChangeRate":0.0297},{"month":10,"riseRate":0.1875,"avgChangeRate":-0.024917},{"month":11,"riseRate":0.25,"avgChangeRate":-0.011357},{"month":12,"riseRate":0.375,"avgChangeRate":0.005962}],"exchange":"ASX","name":"Cellmid","nameEN":"Cellmid"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CDY.AU\",market:\"AU\",,,undefined,":null}}